ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

NCI Picks 11 Centers For Chemical Biology Consortium

October 23, 2009

DCBDC Board Ok’s New Initiative For Training

November 16, 1990

Cancer Statistics: Colorectal Cancer Incidence Declines, Annual Report Finds

May 19, 2000

In Brief: House Passes Bill Extending Saccharin Status To 1981; Execs No Enthusiastic Over New SES

August 3, 1979

New International Policy On Clinical Trials Is Needed, Veronesi Says

October 21, 1983

Racial Disparities Remain In Breast Cancer Care

October 29, 2010